Levy G (1994) Pharmacologic target-mediated drug disposition. Clin Pharmacol Ther 56(3):248–252. https://doi.org/10.1038/clpt.1994.134

Article  PubMed  CAS  Google Scholar 

Svilenov HL, Bester R, Sacherl J, Absmeier R, Peters C, Protzer U, Brockmeyer C, Buchner J (2022) Multimeric ACE2-IgM fusions as broadly active antivirals that potently neutralize SARS-CoV-2 variants. Commun Biol 5(1):1237. https://doi.org/10.1038/s42003-022-04193-z

Article  PubMed  PubMed Central  CAS  Google Scholar 

Schropp J, Khot A, Shah DK, Koch G (2019) Target-Mediated Drug Disposition Model for Bispecific Antibodies: Properties, Approximation, and Optimal Dosing Strategy. CPT Pharmacometrics Syst Pharmacol 8(3):177–187. https://doi.org/10.1002/psp4.12369

Article  PubMed  PubMed Central  CAS  Google Scholar 

Ng CM, Stefanich E, Anand BS, Fielder PJ, Vaickus L (2006) Pharmacokinetics/pharmacodynamics of nondepleting anti-CD4 monoclonal antibody (TRX1) in healthy human volunteers. Pharm Res 23(1):95–103. https://doi.org/10.1007/s11095-005-8814-3

Article  PubMed  CAS  Google Scholar 

Trivedi A, Stienen S, Zhu M, Li H, Yuraszeck T, Gibbs J, Heath T, Loberg R, Kasichayanula S (2017) Clinical pharmacology and translational aspects of bispecific antibodies. Clin Transl Sci 10(3):147–162. https://doi.org/10.1111/cts.12459

Article  PubMed  PubMed Central  CAS  Google Scholar 

Kaushansky K (2006) Lineage-specific hematopoietic growth factors. N Engl J Med 354(19):2034–2045. https://doi.org/10.1056/NEJMra052706

Article  PubMed  CAS  Google Scholar 

Douglass EF Jr, Miller CJ, Sparer G, Shapiro H, Spiegel DA (2013) A comprehensive mathematical model for three-body binding equilibria. J Am Chem Soc 135(16):6092–6099. https://doi.org/10.1021/ja311795d

Article  PubMed  PubMed Central  CAS  Google Scholar 

Betts A, van der Graaf PH (2020) Mechanistic quantitative pharmacology strategies for the early clinical development of bispecific antibodies in oncology. Clin Pharmacol Ther 108(3):528–541. https://doi.org/10.1002/cpt.1961

Article  PubMed  PubMed Central  CAS  Google Scholar 

Keyt BA, Baliga R, Sinclair AM, Carroll SF, Peterson MS (2020) Structure, function, and therapeutic use of IgM antibodies. Antibodies (Basel). https://doi.org/10.3390/antib9040053

Article  PubMed  Google Scholar 

Rujas E, Kucharska I, Tan YZ, Benlekbir S, Cui H, Zhao T, Wasney GA, Budylowski P, Guvenc F, Newton JC, Sicard T, Semesi A, Muthuraman K, Nouanesengsy A, Aschner CB, Prieto K, Bueler SA, Youssef S, Liao-Chan S, Glanville J, Christie-Holmes N, Mubareka S, Gray-Owen SD, Rubinstein JL, Treanor B, Julien JP (2021) Multivalency transforms SARS-CoV-2 antibodies into ultrapotent neutralizers. Nat Commun 12(1):3661. https://doi.org/10.1038/s41467-021-23825-2

Article  PubMed  PubMed Central  CAS  Google Scholar 

Overdijk MB, Strumane K, Beurskens FJ, Ortiz Buijsse A, Vermot-Desroches C, Vuillermoz BS, Kroes T, de Jong B, Hoevenaars N, Hibbert RG, Lingnau A, Forssmann U, Schuurman J, Parren P, de Jong RN, Breij ECW (2020) Dual epitope targeting and enhanced hexamerization by DR5 antibodies as a novel approach to induce potent antitumor activity through DR5 agonism. Mol Cancer Ther 19(10):2126–2138. https://doi.org/10.1158/1535-7163.MCT-20-0044

Article  PubMed  CAS  Google Scholar 

Mager DE, Jusko WJ (2001) General pharmacokinetic model for drugs exhibiting target-mediated drug disposition. J Pharmacokinet Pharmacodyn 28(6):507–532. https://doi.org/10.1023/a:1014414520282

Article  PubMed  CAS  Google Scholar 

Gibiansky L, Gibiansky E, Kakkar T, Ma P (2008) Approximations of the target-mediated drug disposition model and identifiability of model parameters. J Pharmacokinet Pharmacodyn 35(5):573–591. https://doi.org/10.1007/s10928-008-9102-8

Article  PubMed  CAS  Google Scholar 

Mager DE, Krzyzanski W (2005) Quasi-equilibrium pharmacokinetic model for drugs exhibiting target-mediated drug disposition. Pharm Res 22(10):1589–1596. https://doi.org/10.1007/s11095-005-6650-0

Article  PubMed  CAS  Google Scholar 

Marathe A, Krzyzanski W, Mager DE (2009) Numerical validation and properties of a rapid binding approximation of a target-mediated drug disposition pharmacokinetic model. J Pharmacokinet Pharmacodyn 36(3):199–219. https://doi.org/10.1007/s10928-009-9118-8

Article  PubMed  CAS  Google Scholar 

Gibiansky L, Gibiansky E (2010) Target-mediated drug disposition model for drugs that bind to more than one target. J Pharmacokinet Pharmacodyn 37(4):323–346. https://doi.org/10.1007/s10928-010-9163-3

Article  PubMed  CAS  Google Scholar 

Ng CM, Fielder PJ, Jin J, Deng R (2016) Mechanism-Based competitive binding model to investigate the effect of neonatal fc receptor binding affinity on the pharmacokinetic of humanized anti-VEGF monoclonal IgG1 antibody in cynomolgus monkey. AAPS J 18(4):948–959. https://doi.org/10.1208/s12248-016-9911-4

Article  PubMed  CAS  Google Scholar 

Yan X, Chen Y, Krzyzanski W (2012) Methods of solving rapid binding target-mediated drug disposition model for two drugs competing for the same receptor. J Pharmacokinet Pharmacodyn 39(5):543–560. https://doi.org/10.1007/s10928-012-9267-z

Article  PubMed  PubMed Central  Google Scholar 

Wang ZX (1995) An exact mathematical expression for describing competitive binding of two different ligands to a protein molecule. FEBS Lett 360(2):111–114. https://doi.org/10.1016/0014-5793(95)00062-e

Article  PubMed  CAS  Google Scholar 

Gibiansky L, Gibiansky E (2017) Target-mediated drug disposition model for drugs with two binding sites that bind to a target with one binding site. J Pharmacokinet Pharmacodyn 44(5):463–475. https://doi.org/10.1007/s10928-017-9533-1

Article  PubMed  CAS  Google Scholar 

Gibiansky L, Ng CM, Gibiansky E (2024) Target-mediated drug disposition model for drugs with N > 2 binding sites that bind to a target with one binding site. J Pharmacokinet Pharmacodyn. https://doi.org/10.1007/s10928-024-09917-8

Article  PubMed  Google Scholar 

Koch G, Jusko WJ, Schropp J (2017) Target-mediated drug disposition with drug-drug interaction, Part I: single drug case in alternative formulations. J Pharmacokinet Pharmacodyn 44(1):17–26. https://doi.org/10.1007/s10928-016-9501-1

Article  PubMed  PubMed Central  CAS  Google Scholar 

Hayashi N, Tsukamoto Y, Sallas WM, Lowe PJ (2007) A mechanism-based binding model for the population pharmacokinetics and pharmacodynamics of omalizumab. Br J Clin Pharmacol 63(5):548–561. https://doi.org/10.1111/j.1365-2125.2006.02803.x

Article  PubMed  CAS  Google Scholar 

Schwarz G (1978) Estimating the dimension of a model. Ann Statistics. https://doi.org/10.1214/aos/1176344136

Article  Google Scholar 

Haber L, Olson K, Kelly MP, Crawford A, DiLillo DJ, Tavare R, Ullman E, Mao S, Canova L, Sineshchekova O, Finney J, Pawashe A, Patel S, McKay R, Rizvi S, Damko E, Chiu D, Vazzana K, Ram P, Mohrs K, D’Orvilliers A, Xiao J, Makonnen S, Hickey C, Arnold C, Giurleo J, Chen YP, Thwaites C, Dudgeon D, Bray K, Rafique A, Huang T, Delfino F, Hermann A, Kirshner JR, Retter MW, Babb R, MacDonald D, Chen G, Olson WC, Thurston G, Davis S, Lin JC, Smith E (2021) Generation of T-cell-redirecting bispecific antibodies with differentiated profiles of cytokine release and biodistribution by CD3 affinity tuning. Sci Rep 11(1):14397. https://doi.org/10.1038/s41598-021-93842-0

Article  PubMed  PubMed Central  CAS  Google Scholar 

Ginaldi L, Matutes E, Farahat N, De Martinis M, Morilla R, Catovsky D (1996) Differential expression of CD3 and CD7 in T-cell malignancies: a quantitative study by flow cytometry. Br J Haematol 93(4):921–927. https://doi.org/10.1046/j.1365-2141.1996.d01-1720.x

Article  PubMed  CAS